AbbVie (ABBV) Stock Price, News & Analysis

Company Overview

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

Written by Jeffrey Neal Johnson

Key Stats

• Today's Range: $174.63 to $177.40
• 50-Day Range: $164.91 to $203.87
• 52-Week Range: $153.58 to $207.32
• Volume: 1.73 million shs
• Average Volume: 5.59 million shs
• Market Capitalization: $313.26 billion
• P/E Ratio: 61.55
• Dividend Yield: 3.70%
• Price Target: $205.70
• Consensus Rating: Moderate Buy

AbbVie Stock Analysis - MarketRank™

AbbVie scored higher than 99% of companies evaluated by MarketBeat, and ranked 23rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 17 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

AbbVie has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 11.59%

Earnings Growth

Earnings for AbbVie are expected to grow by 11.59% in the coming year, from $10.96 to $12.23 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AbbVie is 61.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.59.

Price to Earnings Ratio vs. Sector

The P/E ratio of AbbVie is 61.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 87.51.

Price to Earnings Growth Ratio

AbbVie has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

AbbVie has a P/B Ratio of 30.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.09% of the outstanding shares of AbbVie have been sold short.

Short Interest Ratio / Days to Cover

AbbVie has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AbbVie has recently decreased by 4.21%, indicating that investor sentiment is improving.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

AbbVie is a leading dividend payer. It pays a dividend yield of 3.53%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

AbbVie has been increasing its dividend for 53 years.

Dividend Coverage

The dividend payout ratio of AbbVie is 227.78%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, AbbVie will have a dividend payout ratio of 53.64% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -2.34

Percentage of Shares Shorted

1.09% of the outstanding shares of AbbVie have been sold short.

Short Interest Ratio / Days to Cover

AbbVie has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AbbVie has recently decreased by 4.21%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.53

News Sentiment

AbbVie has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 28 news articles for AbbVie this week, compared to 31 articles on an average week.

Search Interest

Only 128 people have searched for ABBV on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.

MarketBeat Follows

Only 51 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $310,032.00 in company stock.

Percentage Held by Insiders

Only 0.25% of the stock of AbbVie is held by insiders.

Percentage Held by Institutions

70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABBV Stock Analysis - Frequently Asked Questions

How have ABBV shares performed this year?

AbbVie's stock was trading at $154.97 on January 1st, 2024. Since then, ABBV shares have increased by 13.5% and is now trading at $175.87.
View the best growth stocks for 2024 here.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Wednesday, October, 30th. The company reported $3.00 earnings per share for the quarter, beating analysts' consensus estimates of $2.92 by $0.08. The business's revenue was up 3.8% on a year-over-year basis.
Read the conference call transcript.

Does AbbVie have any subsidiaries?

The following companies are subsidiaries of AbbVie: Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and more.

Who are AbbVie's major shareholders?

AbbVie's top institutional investors include State Street Corp (4.47%), Geode Capital Management LLC (2.05%), Charles Schwab Investment Management Inc. (1.35%) and Franklin Resources Inc. (0.79%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Michael Severino, Robert A Michael, Jeffrey Ryan Stewart, Nicholas Donoghoe, Roxanne S Austin, Carrie C Strom, Elaine K Sorg, Scott T Reents, Henry O Gosebruch, Timothy J Richmond, Perry C Siatis, Kevin K Buckbee and Brian L Durkin.
View institutional ownership trends.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC).

Company Calendar

• Ex-Dividend for 11/15 Dividend: 10/15/2024
• Last Earnings: 10/30/2024
• Dividend Payable: 11/15/2024
• Today: 12/23/2024
• Fiscal Year End: 12/31/2024
• Ex-Dividend for 2/14 Dividend: 1/15/2025
• Dividend Payable: 2/14/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:ABBV
• CUSIP: 00287Y10
• CIK: 1551152
• Web: www.abbvie.com
• Phone: (847) 932-7900
• Fax: 302-655-5049
• Employees: 50,000
• Year Founded: 2013

Price Target and Rating

• Average Stock Price Target: $205.70
• High Stock Price Target: $225.00
• Low Stock Price Target: $180.00
• Potential Upside/Downside: +17.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 24 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.88
• Trailing P/E Ratio: 60.97
• Forward P/E Ratio: 16.02
• P/E Growth: 1.92
• Net Income: $4.86 billion
• Net Margins: 9.22%
• Pretax Margin: 12.96%
• Return on Equity: 244.01%
• Return on Assets: 13.44%

Debt

• Debt-to-Equity Ratio: 9.64
• Current Ratio: 0.65
• Quick Ratio: 0.54

Sales & Book Value

• Annual Sales: $55.53 billion
• Price / Sales: 5.59
• Cash Flow: $15.92 per share
• Price / Cash Flow: 11.03
• Book Value: $5.78 per share
• Price / Book: 30.38

Miscellaneous

• Outstanding Shares: 1,767,140,000
• Free Float: 1,762,722,000
• Market Cap: $310.27 billion
• Optionable: Optionable
• Beta: 0.58